AEON Biopharma, Inc. Selling, General and Administrative Expense
AEON Biopharma, Inc. (AEON) reported Selling, General and Administrative Expense of $2.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-12
- AEON Biopharma, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $2.99M, a 8.20% decline year-over-year.
- AEON Biopharma, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $3.90M, a 24.90% increase year-over-year.
- AEON Biopharma, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $3.89M, a 48.04% increase year-over-year.
- AEON Biopharma, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $1.93M, a 36.50% decline year-over-year.
- AEON Biopharma, Inc. selling, general and administrative expense for fiscal 2025 was $12.21M, a 10.52% decline from fiscal 2024.
- AEON Biopharma, Inc. selling, general and administrative expense for fiscal 2024 was $13.64M.
- AEON Biopharma, Inc. selling, general and administrative expense for fiscal 2022 was $13.68M.
| Period end | Selling, General and Administrative Expense 1 month | Selling, General and Administrative Expense 2 month | Selling, General and Administrative Expense 2 month as first filed | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 5 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 7 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.99M 10-Q · filed 2026-08-12 | $6.89M 10-Q · filed 2026-08-12 | $10.79M derived: sum of 3 quarters · filed 2026-08-12 | $12.72M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | $3.90M 10-Q · filed 2026-05-14 | $7.79M derived: sum of 2 quarters · filed 2026-05-14 | $9.73M derived: sum of 3 quarters · filed 2026-05-14 | $12.99M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.83M derived: sum of 2 quarters · filed 2026-03-30 | $9.08M derived: sum of 3 quarters · filed 2026-08-12 | $12.21M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $1.93M 10-Q · filed 2025-11-14 | $5.19M derived: sum of 2 quarters · filed 2026-08-12 | $8.32M 10-Q · filed 2025-11-14 | $10.95M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | $3.26M 10-Q · filed 2026-08-12 | $6.38M 10-Q · filed 2026-08-12 | $9.01M derived: sum of 3 quarters · filed 2026-08-12 | $12.06M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | $3.13M 10-Q · filed 2026-05-14 | $5.75M derived: sum of 2 quarters · filed 2026-05-14 | $8.80M derived: sum of 3 quarters · filed 2026-05-14 | $12.12M derived: sum of 4 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.67M derived: sum of 2 quarters · filed 2026-03-30 | $8.99M derived: sum of 3 quarters · filed 2026-03-30 | $13.64M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $3.04M 10-Q · filed 2025-11-14 | $6.37M derived: sum of 2 quarters · filed 2025-11-14 | $11.01M 10-Q · filed 2025-11-14 | ||||||
| 2024-06-30 | $3.32M 10-Q · filed 2025-08-12 | $7.97M 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | $4.65M 10-Q · filed 2025-05-14 | ||||||||
| 2023-12-31 | $9.95M 10-K · filed 2025-03-24 | ||||||||
| 2023-09-30 | $5.26M 10-Q/A · filed 2024-03-29 | ||||||||
| 2023-07-21 | $1.05M 10-Q · filed 2024-11-13 | $9.84M 10-K · filed 2025-03-24 | |||||||
| 2023-06-30 | $4.95M 10-Q · filed 2024-08-12 | $8.79M 10-Q · filed 2024-08-12 | $14.29M derived: sum of 3 quarters · filed 2024-08-12 | $16.73M derived: sum of 4 quarters · filed 2024-08-12 | |||||
| 2023-03-31 | $3.84M 10-Q · filed 2024-05-14 | $9.35M derived: sum of 2 quarters · filed 2024-05-14 | $11.78M derived: sum of 3 quarters · filed 2024-05-14 | ||||||
| 2022-12-31 | $5.50M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-05-14 | $7.94M derived: sum of 2 quarters · filed 2024-05-14 | $13.68M 10-K/A · filed 2024-05-14 | ||||||
| 2022-09-30 | $2.44M 10-Q/A · filed 2024-03-29 | $8.17M 10-Q/A · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |